Evidence map›Paper›PMID 35143587›Full record

ArticlePLoS pathogens2022

The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.

Timothy Carroll, Douglas Fox, Neeltje van Doremalen, Erin Ball, Mary Kate Morris, Alicia Sotomayor-Gonzalez, Venice Servellita, Arjun Rustagi, Claude Kwe Yinda, Linda Fritts and 10 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Longitudinal analyses usingAntiviral research · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Timothy CarrollCalifornia National Primate Research Center, University of California Davis, Davis, California, United States of America.ORCID 0000-0002-3459-3364
Douglas FoxUniversity of California, Berkeley, Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis, Berkeley, California, United States of America.ORCID 0000-0001-9260-4079
Neeltje van DoremalenLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Erin BallDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.ORCID 0000-0002-8464-6612
Mary Kate MorrisDivision of Viral and Rickettsial Diseases, California Department of Public Health, Richmond, California, United States of America.ORCID 0000-0003-0143-5615
Alicia Sotomayor-GonzalezDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-8930-745X
Venice ServellitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-1745-4012
Arjun RustagiDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, United States of America.ORCID 0000-0002-6921-1012
Claude Kwe YindaLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.ORCID 0000-0002-5195-5478
Linda FrittsCalifornia National Primate Research Center, University of California Davis, Davis, California, United States of America.ORCID 0000-0003-3703-4629
Julia Rebecca PortLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.ORCID 0000-0002-0489-6591
Zhong-Min MaCalifornia National Primate Research Center, University of California Davis, Davis, California, United States of America.ORCID 0000-0003-3713-7337
Myndi G HolbrookLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.ORCID 0000-0003-2376-2633
Jonathan SchulzLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Catherine A BlishDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, United States of America.ORCID 0000-0001-6946-7627
Carl HansonDivision of Viral and Rickettsial Diseases, California Department of Public Health, Richmond, California, United States of America.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0003-2915-2094
Vincent MunsterLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Sarah StanleyUniversity of California, Berkeley, Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis, Berkeley, California, United States of America.ORCID 0000-0002-4182-9048
Christopher J MillerCalifornia National Primate Research Center, University of California Davis, Davis, California, United States of America.ORCID 0000-0002-1381-1975
National Institutes of Health · USUniversity of California, Davis · USUniversity of California, San Francisco · USCalifornia Department of Public Health · USStanford University · USUniversity of California, Berkeley · US

Funding

Virus Ecology UnitZIAAI001179 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2013 to 2025
$24.3M
EMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8M
Virus Ecology Unit - COVID-19 responseZIAAI001289 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2020 to 2025
$4.7M
How did a vaccine enhance HIV acquisitionR01AI118590 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLER, CHRISTOPHER JAMES · 2015 to 2019
$3.3M
Identification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profilingR21AI129455 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2017 to 2018
$436k
Intramural NIH HHS ZIA AI001179NIAID NIH HHS R01 AI118590NIAID NIH HHS R21 AI129455NIAID NIH HHS T32 AI007502
6 · The paper itself

Abstract

As novel SARS-CoV-2 variants continue to emerge, it is critical that their potential to cause severe disease and evade vaccine-induced immunity is rapidly assessed in humans and studied in animal models. In early January 2021, a novel SARS-CoV-2 variant designated B.1.429 comprising 2 lineages, B.1.427 and B.1.429, was originally detected in California (CA) and it was shown to have enhanced infectivity in vitro and decreased antibody neutralization by plasma from convalescent patients and vaccine recipients. Here we examine the virulence, transmissibility, and susceptibility to pre-existing immunity for B 1.427 and B 1.429 in the Syrian hamster model. We find that both variants exhibit enhanced virulence as measured by increased body weight loss compared to hamsters infected with ancestral B.1 (614G), with B.1.429 causing the most marked body weight loss among the 3 variants. Faster dissemination from airways to parenchyma and more severe lung pathology at both early and late stages were also observed with B.1.429 infections relative to B.1. (614G) and B.1.427 infections. In addition, subgenomic viral RNA (sgRNA) levels were highest in oral swabs of hamsters infected with B.1.429, however sgRNA levels in lungs were similar in all three variants. This demonstrates that B.1.429 replicates to higher levels than ancestral B.1 (614G) or B.1.427 in the oropharynx but not in the lungs. In multi-virus in-vivo competition experiments, we found that B.1. (614G), epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs. In the nasal cavity, B.1. (614G), gamma, and epsilon dominate, but the highly infectious alpha variant also maintains a moderate size niche. We did not observe significant differences in airborne transmission efficiency among the B.1.427, B.1.429 and ancestral B.1 (614G) and WA-1 variants in hamsters. These results demonstrate enhanced virulence and high relative oropharyngeal replication of the epsilon (B.1.427/B.1.429) variant in Syrian hamsters compared to an ancestral B.1 (614G) variant.

Indexed as

AnimalsCOVID-19Disease Models, AnimalFemaleHumansLungMaleMesocricetusMutationSARS-CoV-2Spike Glycoprotein, CoronavirusVirulenceSpike Glycoprotein, Coronavirus

Identifiers

PMID35143587
PMCPMC8865701
OpenAlexW4220860951

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.